-
Journal of Experimental Pharmacology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus
Original Research
(2709) Views (2044) Full article downloads
Authors: R Pradeep Kumar, D Sujatha, TS Mohamed Saleem, C Madhusudhana Chetty, D Ranganayakulu
Published Date February 2010
Volume 2010:2 Pages 29 - 36
DOI: http://dx.doi.org/10.2147/JEP.S8947
R Pradeep Kumar,1 D Sujatha,2 TS Mohamed Saleem,1 C Madhusudhana Chetty,1 D Ranganayakulu2
1Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet, India; 2Department of Pharmacology, Sri Padmavathi School of Pharmacy, Tirupathi, India
Abstract: Herbal drugs are frequently considered to be less toxic and also free from side effects, than synthetic ones. Hence, the present study was designed to investigate one such combination of herbal drugs, Asystasia gangetica and Morus indica for their antidiabetic and antioxidant potential against alloxan-induced diabetes in albino rats. The effect of both individual and a combination of Asystasia gangetica and Morus indica on blood glucose and liver glycogen were studied in the diabetic rats. The study also assessed for the effect of selected plant extracts for their effect on Superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH) and Lipid peroxidation (LPO) in the homogenates of the pancreas. The results of the present study attests significant antidiabetic and antioxidant potential for the selected plants individually and also in combination as a prominent decrease in blood glucose and liver glycogen was observed in the rats treated with the extracts of the selected plants. Similarly, the levels of the protective antioxidant enzymes like SOD, CAT and GSH were increased along with decrease in the LPO levels. The present study provides a scientific evidence for antidiabetic and antioxidant potential of Asystasia gangetica and Morus indica. Further studies to isolate bioactive compounds will pave the way to identify potential lead compounds for developing safe and efficacious antidiabetic agents.
Keywords: hypoglycemic effect, herbal drugs, lipid peroxidation, hyperglycemia, diabetic animals
Other articles by Mr TSM Saleem
Dronedarone in the management of atrial fibrillation
High-density lipoproteins: a novel therapeutic target for cardiovascular disease
Readers of this article also read:
Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose–insulin homeostasis in animal models
Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Effects of an oral dose of l-glutamic acid on circulating neurotransmitters: Possible roles of the C1(Ad) and the A5(NA) pontomedullary nuclei
Effect of amlodipine, a calcium channel antagonist, on gonadal steroid of male wistar albino rats
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotection of lacidipine against gentamycin-induced nephrotoxicity in albino rats
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




